PRINCETON, N.J. - Bristol Myers Squibb (NYSE:BMY) reported positive results from its Phase 3 SCOUT-HCM trial evaluating Camzyos (mavacamten) in adolescents aged 12 to 17 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), according to a press release statement.
The trial met its primary endpoint, showing a statistically significant reduction in Valsalva left ventricular outflow tract gradient at Week 28 compared to placebo, with a least-squares mean difference of -48.0 mm Hg (P).
The trial also showed improvements in secondary endpoints including resting and post-exercise LVOT gradients, with least-squares mean differences of -47.0 mm Hg and -41.7 mm Hg respectively. Additional improvements were observed in maximal left ventricular wall thickness and diastolic function measures.
Safety findings were similar between the Camzyos and placebo groups. Treatment-emergent adverse events occurred in 18 patients receiving Camzyos versus 17 on placebo. No treatment discontinuations, deaths, cases of atrial fibrillation, or symptomatic heart failure were reported during the 28-week period. No patient experienced left ventricular ejection fraction below 50%. The positive trial results come as Bristol Myers shares trade near their 52-week high, with the stock delivering a 36% return over the past six months. Trading at a P/E ratio of 16.91 with a 4.3% dividend yield, the stock appears undervalued based on InvestingPro Fair Value analysis. Investors seeking deeper insights can access comprehensive analysis through the company's Pro Research Report, one of 1,400+ available for US equities.
The data were presented at the American College of Cardiology's Annual Scientific Session & Expo 2026 and published simultaneously in The New England Journal of Medicine.
Camzyos is currently approved in more than 60 countries for adults with symptomatic oHCM. The medication carries a boxed warning regarding risk of heart failure and is available only through a restricted REMS program requiring monitoring of left ventricular ejection fraction.
Bristol Myers Squibb stated it will present 56-week data from the ongoing trial at a future medical congress.
In other recent news, Bristol Myers Squibb reported positive interim Phase 3 results from its SUCCESSOR-2 study, which evaluated the combination of oral mezigdomide with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. The combination treatment showed significant improvement in progression-free survival compared to carfilzomib and dexamethasone alone. Additionally, the U.S. Food and Drug Administration approved Sotyktu for treating adults with active psoriatic arthritis, marking it as the first tyrosine kinase 2 inhibitor approved for this condition. This approval was based on the results from two Phase 3 clinical trials, POETYK PsA-1 and POETYK PsA-2.
Bristol Myers Squibb also expanded its collaboration with insitro to develop additional therapeutic programs for amyotrophic lateral sclerosis, with two new targets identified. Jefferies raised its price target for Bristol Myers Squibb shares to $70 from $68, maintaining a Buy rating, citing positive interim results from the SUCCESSOR-2 trial. Meanwhile, Raymond James reiterated a Market Perform rating following the presentation of preliminary data on the company's PRMT5 inhibitor navlimetostat. The data showed an objective response rate of 18% in a monotherapy cohort, with a disease control rate above 70%. These developments reflect ongoing progress in Bristol Myers Squibb's research and clinical trials.